Biotech pipeline is outpaced by antibacterial resistance, new BIO report saysnews2022-02-15T17:18:37+00:00February 15th, 2022|FierceBiotech|
Merck gets ahead of the Curve, inking oncology and neurology drug discovery deal with emerging British biotechnews2022-02-15T17:15:44+00:00February 15th, 2022|FierceBiotech|
UCB, Novartis and more pile into SpliceBio series A, ponying up $57M to tackle a big barrier to gene therapynews2022-02-15T17:06:15+00:00February 15th, 2022|FierceBiotech|
A new SPAC decides to enter murky waters to hunt for biotechs in downsized $75M IPOnews2022-02-15T16:22:20+00:00February 15th, 2022|FierceBiotech|
IQVIA sees 2021 revenues jump 22% led by strong service growthnews2022-02-15T14:58:18+00:00February 15th, 2022|FierceBiotech|
Larimar kept in limbo as FDA maintains clinical hold on leading candidatenews2022-02-15T14:21:42+00:00February 15th, 2022|FierceBiotech|
Legend’s early-stage CAR-T on FDA hold after single patient dosednews2022-02-15T13:56:44+00:00February 15th, 2022|FierceBiotech|
Intellia-ONK ink up to $920M pact for 5 CRISPR-edited cancer cell therapiesnews2022-02-15T13:47:17+00:00February 15th, 2022|FierceBiotech|
AC Immune’s Janssen-partnered Alzheimer’s vaccine spurs tau-attacking antibodies in early-stage trialnews2022-02-15T13:36:51+00:00February 15th, 2022|FierceBiotech|
Lilly reunites with ImmunoGen to expand into ADCs, paying $13M upfront and $1.7B on the back endnews2022-02-15T12:57:19+00:00February 15th, 2022|FierceBiotech|
